Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply

Affiliations

¹ Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK.
² Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK; Department of Gastroenterology, UCL Institute of Liver and Digestive Diseases, Royal Free Hospital, London, UK.
³ Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴ Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK. Electronic address: mp372@cam.ac.uk.

Comment

Nurulamin M Noor et al. Lancet Gastroenterol Hepatol. 2024 Jul.

. 2024 Jul;9(7):592-594.

doi: 10.1016/S2468-1253(24)00150-X.

¹ Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK.
² Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK; Department of Gastroenterology, UCL Institute of Liver and Digestive Diseases, Royal Free Hospital, London, UK.
³ Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴ Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK. Electronic address: mp372@cam.ac.uk.

No abstract available

Comment on

Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
Bourgonje AR, Visschedijk MC, Festen EAM, Weersma RK, Dijkstra G. Bourgonje AR, et al. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):590-591. doi: 10.1016/S2468-1253(24)00120-1. Lancet Gastroenterol Hepatol. 2024. PMID: 38870963 No abstract available.
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
Satsangi J, Nowak J, Kalla R, Colombel JF. Satsangi J, et al. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):591-592. doi: 10.1016/S2468-1253(24)00082-7. Lancet Gastroenterol Hepatol. 2024. PMID: 38870964 No abstract available.
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
Borkar V, Lunagariya Y, Chopra S, Sasikumar D, Ingle M. Borkar V, et al. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):591. doi: 10.1016/S2468-1253(24)00112-2. Lancet Gastroenterol Hepatol. 2024. PMID: 38870965 No abstract available.
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
Chen R, Zhang S. Chen R, et al. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):592. doi: 10.1016/S2468-1253(24)00077-3. Lancet Gastroenterol Hepatol. 2024. PMID: 38870967 No abstract available.